Physician profile
Mark Alan Stern
NPI 1407882459
$9,197.51
in general payments reported to CMS, 2019-2025
42 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $896 · 2021: $1,276 · 2022: $754 · 2023: $1,091 · 2024: $2,034 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,038 · Education: $51.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,038.18 |
| Education | $51.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,177.15 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $973.29 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $795.59 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $512.56 | 2022-2025 | Dupixent |
| Romark Laboratories, Lc | $421.03 | 2019-2020 | |
| Ardelyx, INC. | $420.79 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $406.94 | 2019-2025 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $317.38 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $315.24 | 2019-2025 | Livdelzi |
| Pfizer INC. | $306.41 | 2019-2025 | |
| Lilly USA, LLC | $294.58 | 2023-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $239.72 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $202.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $182.12 | 2022-2025 | |
| Braintree Laboratories, INC. | $174.34 | 2019-2024 | Sutab, Suflave |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $155.02 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $148.74 | 2019-2023 | Injectafer |
| Celgene Corporation | $125.80 | 2023-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $111.07 | 2019-2024 | Linzess |
| Celltrion USA INC. | $106.72 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $84.83 | 2024-2025 | Iqirvo |
| Csl Behring | $80.60 | 2021-2023 | Kcentra |
| Amgen INC. | $67.42 | 2020-2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $55.79 | 2020-2024 | Talicia |
| Novo Nordisk INC | $51.51 | 2025 | Wegovy |
| Qol Medical, LLC | $51.30 | 2024-2025 | Sucraid, Sucraid |
| Ucb, INC. | $46.64 | 2019 | |
| Organon LLC | $45.06 | 2025 | Renflexis, Hadlima |
| Alfasigma USA, INC. | $42.58 | 2020 | |
| Nestle Healthcare Nutrition INC. | $38.40 | 2021 | |
| Fresenius Kabi USA, LLC | $37.36 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $32.64 | 2024 | |
| Amag Pharmaceuticals, INC. | $30.33 | 2019-2021 | |
| Allergan, INC. | $25.95 | 2019 | |
| Biogen, INC. | $21.82 | 2019 | |
| Tempus Ai, INC | $21.14 | 2024 | |
| Endo Pharmaceuticals INC. | $17.54 | 2019 | |
| Shionogi INC | $17.25 | 2019 | |
| Capsovision, INC. | $16.94 | 2023 | Capsocam Plus |
| Intra-Sana Laboratories | $12.67 | 2022 | |
| Boston Scientific Corporation | $12.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.